Activation of IGF1, TGF-β and Wnt/β-catenin signaling, NRIP1, Nrf2, SREBP-LXRα, PI3K/AKT, CMYC, CEBPβ, transcriptional factor SP1, NFκB, IL1B and IL6, VEGFA, EGF, FGF2 and other upstream regulators, and downregulation of PPARs and p53 was predicted to be associated with NASH (Figure 3). The gene discussed is MYC; the disease is metabolic dysfunction-associated steatohepatitis.